Institute of Medicine Elects Class of 80 New Members

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

New members are elected by current active members through a selective process that recognizes individuals who have made major contributions to the advancement of the medical sciences, health care, and public health.

A diversity of talent among IOM’s membership is assured by the institute’s charter, which says that at least one-quarter of the membership is selected from outside the health professions, including fields such as the law, engineering, social sciences and the humanities.

The newly elected members raise IOM’s total active membership to 1,798 and the number of foreign associates to 128. With an additional 86 members holding emeritus status, IOM’s total membership is 2,012.

The full list is available on the IOM website. Members in the cancer research field include:

  • José Baselga, physician-in-chief and chief medical officer of Memorial Sloan Kettering Cancer Center, and president-elect of the American Association of Cancer Research
  • Carol Bradford, the Charles J. Krause collegiate professor and chair of the Department of Otolaryngology-Head and Neck Surgery at the University of Michigan
  • Lewis Cantley, director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College/New York-Presbyterian Hospital
  • E. Antonio Chiocca, neurosurgeon-in-chief of the Department of Neurosurgery and co-director of the Institute for the Neurosciences at Brigham and Women’s/Faulkner Hospital; surgical director of the Center for Neuro-oncology at Dana-Farber Cancer Institute; and the Harvey W. Cushing professor of neurosurgery at Harvard Medical School
  • Joseph DeSimone, chancellor’s eminent professor of chemistry and William R. Kenan Jr. distinguished professor of chemistry in the Departments of Chemistry and Pharmacology at University of North Carolina and North Carolina State University, Chapel Hill
  • James Economou, vice chancellor for research and Beaumont professor of surgery at the University of California, Los Angeles
  • Todd Golub, a Howard Hughes Medical Institute investigator; chief scientific officer of the Broad Institute of Harvard and the Massachusetts Institute of Technology; and the Charles A. Dana investigator at Dana-Farber Cancer Institute
  • James Hill, Anschutz Professor in the departments of pediatrics and medicine, and director of the Anschutz Health and Wellness Center at the University of Colorado
  • Paul Khavari, professor and chairman of the Department of Dermatology at Stanford University
  • Brian Kobilka, professor of molecular and cellular physiology at the Stanford University School of Medicine
  • Guillermina Lozano, professor and chair of the Department of Genetics at MD Anderson Cancer Center
  • David Piwnica-Worms, professor and chair of the Department of Cancer Systems Imaging and deputy head of the Division of Diagnostic Imaging at MD Anderson Cancer Center
  • Margaret Shipp, chief of the Division of Hematology Neoplasia at Dana-Farber Cancer Institute
  • Dan Theodorescu, the Paul A. Bunn cancer research chair, professor of surgery and pharmacology, and director of the University of Colorado Comprehensive Cancer Center

YOU MAY BE INTERESTED IN

“I don’t know of a single grant that left my desk that was not approved and funded,” NCI Director Anthony G. Letai said on this episode of The Cancer Letter Podcast. https://open.spotify.com/episode/2PFYGwliBDYEbxBXFd9MtB?si=95DNBAy0QGSKBX31_uETEA This episode is available on Spotify, Apple Podcasts, and Youtube. Letai recapped his first year as NCI director in conversation with Paul Goldberg,...

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login